Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Jun 30, 2022
Revenue for the three and six months ended June 30, 2022 was $5.5 million and $9.1 million, respectively, compared to $3.1 million and $3.5 million for the same periods in 2021
As of June 30, 2022, Adaptimmune had cash and cash equivalents of $97.8 million and Total Liquidity of $258.1 million.
2Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
For Fiscal Year Ending Dec 31, 2021
For complete information regarding our financials, see our periodic filings